Vascular endothelial growth factor targeted therapy in the perioperative setting: Implications for patient care

The Lancet Oncology

Volumn 11, Issue 4, 2010, Pages 373-382

  Bose, Debashish ^a   Meric Bernstam, Funda ^a   Hofstetter, Wayne ^a   Reardon, David A ^b   Flaherty, Keith T ^c   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BIBF 1120; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMC 1121B; IRINOTECAN; MOTESANIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; SEMAXANIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANASTOMOSIS LEAKAGE; BILE DUCT CANCER; BILE LEAKAGE; BLEEDING; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEARING LOSS; HEMATOMA; HUMAN; HYPERTENSION; INCISIONAL HERNIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PLASMA HALF LIFE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SMALL INTESTINE PERFORATION; STOMACH CANCER; THROMBOSIS; TINNITUS; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHEMOTHERAPY, ADJUVANT; HUMANS; INDOLES; NEOADJUVANT THERAPY; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PYRIDINES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 77950339501     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70341-9     Document Type: Review

References (95)

1. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
2. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
3. Bergers G, Hanahan D Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
4. Evensen L, Micklem DR, Blois A, et al. Mural cell associated VEGF is required for organotypic vessel formation. PLoS One 2009, 4:e5798.
5. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
6. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001, 193:1005-1014.
7. Jain RK Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
8. Lambrechts D, Carmeliet P VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 2006, 1762:1109-1121.
9. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001, 28:131-138.
10. Podar K, Anderson KC The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
11. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
12. Ellis LM Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 2006, 33(5 suppl 10):S1-S7.
13. Ellis LM, Hicklin DJ VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
14. Gaur P, Bose D, Samuel S, Ellis LM Targeting tumor angiogenesis. Semin Oncol 2009, 36(2 suppl 1):S12-S19.
15. Kerbel RS Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
16. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002, 105:43-47.
17. Cornacoff JB, Howk K, Pikounis B, et al. Development of a method for the evaluation of wound tensile strength in cynomolgus macaques. J Pharmacol Toxicol Methods 2008, 57:74-79.
18. van Buren G, Yang A, Dallas N, et al. Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008, 26:1836-1842.
19. Chen HX, Cleck JN Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
20. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008, 62:779-786.
21. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
22. Houk BE, Bello CL, Kang D, Amantea M A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009, 15:2497-2506.
23. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005, 16:1688-1694.
24. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12:426-437.
25. Ellis LM, Curley SA, Grothey A Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005, 23:4853-4855.
26. Eng C Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 2009, 6:207-218.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
29. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
30. Chun Y-S, Laurent A, Maru D, et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009, 10:278-286.
31. D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007, 14:759-765.
32. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835.
33. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008, 26:5254-5260.
34. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008, 206:96-106.
35. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
36. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009, 16:35-41.
37. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008, 15:2765-2772.
38. Okines A, del Puerto O, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966. Br J Cancer 2009, 101:1033-1038.
39. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
40. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
41. Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 2008, 19:1659-1661.
42. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
43. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
44. Sugrue MM, Purdie DM, Feng S, et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS). Proc Am Soc Clin Oncol 2008, 26. abstr 4105.
45. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 27:3385-3390.
46. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. Proc Am Soc Clin Oncol 2009, 27. abstr LBA4.
47. Saif MW, Elfiky A, Salem RR Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007, 14:1860-1869.
48. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 2009, 3. CD005392.
49. Hapani S, Chu D, Wu S Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
50. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008, 19:577-582.
51. Sugrue MM, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Proc Am Soc Clin Oncol 2006, 24. abstr 3535.
52. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
53. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 2008, 26. abstr LBA1011.
54. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009, 27. abstr 1005.
55. Higa GM, Abraham J Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 2009, 9:999-1007.
56. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24:769-777.
57. Denduluri N, Yang SX, Berman AW, et al. Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 2008, 7:15-20.
58. Ryan PD, Isakoff SJ, Golshan M, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. Proc Am Soc Clin Oncol 2009, 27. abstr 551.
59. Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer Drugs 2008, 19:217-219.
60. Forero-Torres A, Jones C, Percent I, et al. A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. Proc Am Soc Clin Oncol 2008, 26. abstr 625.
61. Waintraub SE, Tuchman V The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer. Proc Am Soc Clin Oncol 2009, 27(suppl 15). abstr 11524.
62. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009, 62:707-709.
63. Golshan M, Garber J, Gelman R, et al. Surgical complications and the use of neoadjuvant bevacizumab. Proceedings of the 97th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 9-13, 2009; abstract 43.
64. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
65. Motzer RJ, Basch E Targeted drugs for metastatic renal cell carcinoma. Lancet 2007, 370:2071-2073.
66. Bukowski RM Renal cell carcinoma: a model system for novel drug development?. Clin Genitourin Cancer 2008, 6:7-8.
67. Yang CC, Chu KC, Yeh WM Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J Clin Lab Anal 2003, 17:85-89.
68. Rabbani F, Grimaldi G, Russo P Multiple primary malignancies in renal cell carcinoma. J Urol 1998, 160:12555-12559.
69. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
70. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
71. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008, 72:864-868.
72. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009, 181:518-523.
73. Rathmell WK, Cowey C, Amin C, et al. A pilot study of neoadjuvant sorafenib for the treatment of stage T2 or higher renal cell carcinoma. Genitourinary Cancers Symposium; Orlando, FL, USA; Feb 26-28, 2009; abstr 315.
74. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4076-4081.
75. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008, 180:94-98.
76. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
77. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
78. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
79. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009, 24:677-685.
80. Finley DJ, Shen R, Rizvi A, Rusch VW, Kris MG Operative outcomes using bevacizumab, docetaxel, and cisplatin as induction therapy in patients with operable lung cancer. Proc Am Soc Clin Oncol 2009, 27. abstr 7559.
81. Gressett SM, Shah SR Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009, 43:490-501.
82. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007, 7:91.
83. Wen PY, Kesari S Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
84. Norden AD, Drappatz J, Wen PY Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7:1152-1160.
85. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 2008, 9:1-22.
86. Desjardins A, Reardon DA, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14:7068-7073.
87. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:12535-12559.
88. Stark-Vance V Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-oncol 2005, 7. abstr 342.
89. Cloughesy TF, Prados MD, Mikkelsen T A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Proc Am Soc Clin Oncol 2008, 26. abstr 2010b.
90. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
91. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
92. Lai A, Nghiemphu P, Green R Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. Proc Am Soc Clin Oncol 2009, 27. abstr 2000.
93. Vredenburgh JJ, Desjardins A, Reardon DA Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2009, 27. abstr 2015.
94. Gilbert MR, Wang M, Aldape K RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). Proc Am Soc Clin Oncol 2009, 27. abstr 2011.
95. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71:1372-1380.